Targets › PCNA
1 program from 1 company in 2 trials: 2 Phase 1; Oncology; next expected readout Jan 2027.
Confers DNA tethering and processivity to DNA polymerases and other proteins. Auxiliary protein of DNA polymerase delta and epsilon, is involved in the control of DNA replication by increasing the polymerases' processivity during elongation of the leading strand. (UniProt, P12004)
Open in Phaseline: the race on PCNA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| City of Hope Medical Center | AOH1996 PCNA inhibitor | PCNA | Phase 1 | Recurrent Acute Myeloid Leukemia; Refractory Malignant Solid Neoplasm | Jan 2027 |
Recurrent Acute Myeloid Leukemia (1) Refractory Malignant Solid Neoplasm (1)
other (1)
City of Hope Medical Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.